We work at the convergence of science, medicine, and engineering to reinvent the process of drug discovery and treatment.
The Harvard Program in Therapeutic Science (HiTS) is an academic research and education program that advances the fundamental science underlying human diseases and drug discovery in order to improve patient care.
Our faculty, trainees, and staff study disease using innovative approaches that fuse laboratory investigation, clinical research, and computer science to accelerate the invention of the life-saving medicines and precision diagnostics that are needed to optimally treat individual patients.
HiTS brings together two approaches:
The Laboratory of Systems Pharmacology makes it possible to study the changes that promote disease and the ways in which therapeutic drugs function at the molecular level.
The Center for Regulatory Science focuses on evaluating drugs in clinical trials and balancing the benefits and risks of new medicines.
Explore HiTS Research
News, Events, & Updates
Regulatory Science Forum
Fellows Showcase
- Ahhyung Choi – “Advancing Regulatory Science through Perinatal Pediatric Pharmacoepidemiology”
- Ning Lyu – “Pharmacoepidemiology Studies in Children and Adolescents Using Real-World Evidence”
- Susmitha Wunnava – “Implantable Medical Devices in the Care of Children with Congenital Heart Disease”
- Maximilian Siebert – “Postmarketing Requirements and Commitments”
Tuesday, February 4th, 12:00pm ET
LSP in the News
“The LSP welcomes pathology expert Sandro Santagata as new Associate Director”
Twitter @Harvard_Lab
Publication Spotlight! 🔦 The research team mapped the immune response in fallopian tube precursors of High-Grade Serous Ovarian Cancer by integrating high-plex imaging and spatial transcriptomics.
📚 https://doi.org/10.1158/2159-8290.CD-24-1366
@TanjinaKader @JiaRenLin Clemens Hug @SantagataMDPhD
Check out the latest issue of eLudwigNews https://conta.cc/3C01hDm and sign up for our newsletter to stay up to date on all Ludwig news http://bit.ly/LCRnews
First lab tweet! Sharing new papers:
PRINT Using Perturb-map, we show how ovarian tumors resist immunotherapy
PREPRINT Developed new technology to easily generate cell-targeted LNP-RNA @SantagataMDPhD @JoshuaBrodyMD @yizhoudonglab
Mark your calendars! The #NIHCommonFund is hosting a 2-day workshop on 3/11-3/12 to hear from the community about ideas to enable #PrecisionMedicine with #AI through the integration of #MedicalImaging with other #Data types. Register today! https://go.nih.gov/awiS2id
@ronny_drapkin @TanjinaKader @JiaRenLin YES! Excellent teamwork studying the development of fallopian tube precursors to high grade serous ovarian cancer.
Very proud of the impressive effort by @TanjinaKader, @JiaRenLin, Clemens Hug, and team. A total joy to work with them and colleagues.
And a delight to be able to…